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Abstract
Although pain is one of the most prevalent and bothersome symptoms children with cancer
experience, evidence-based guidance regarding assessment and management is lacking. With
44 international, multidisciplinary healthcare professionals and nine patient representatives, we
aimed to develop a clinical practice guideline (followingGRADEmethodology), addressing assess-
ment and pharmacological, psychological, and physical management of tumor-, treatment-, and
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procedure-related pain in children with cancer. In this paper, we present our thorough methodol-
ogy for this development, including the challenges we faced and how we approached these. This
lays the foundation for our clinical practice guideline, for which there is a high clinical demand.
K EYWORDS
clinical practice guideline, evidence-basedmedicine, pain, pediatric oncology, supportive care
1 INTRODUCTION
Pain in children with cancer has been well acknowledged and puts
great burden on patients and their families.1,2 For this reason, pro-
viding age-appropriate pain assessments and treatment strategies
to reduce is a priority. Pain in children treated for cancer can
have multiple origins, such as the tumor itself (e.g., pain associated
with bone metastases), adverse effects of anticancer treatment (e.g.,
chemotherapy-induced neuropathic pain), or painful and distressing
procedures that children with cancer undergo frequently (e.g., access-
ing a central venous access port).3–5
Even though reducing pain has been acknowledged as being
of utmost importance, there is no uniform guideline that advises
on assessment and management of pain in children with cancer.
This is unfortunate, as high-quality evidence-based guidelines, also
called clinical practice guidelines (CPGs), have been shown repeat-
edly to improve patient outcomes.6,7 Clinical practice guidelines
include a systematic review of evidence, thus providing clinicians
with an overview of the current best available evidence.8 Rec-
ommendations are then based upon the evidence and formulated
by a representative multidisciplinary panel including professionals
and patient representatives. Justifications and subgroup consider-
ations are included to provide insight as to why specific treat-
ments should or should not be provided and to which patients.
In addition, by summarizing the available evidence research gaps
are identified that help in composing and prioritizing a research
agenda.
We know that children experience pain as one of the most both-
ersome symptoms of cancer and its treatment, and parents even des-
ignated pain as the most problematic are for their child undergo-
ing cancer treatment.9,10 With the current lack of evidence-based
guidance in this area, and the existing large variations in daily prac-
tice, a CPG could be pivotal to improve pain outcomes and quality of
life.11
We therefore initiated the development of a comprehensive CPG
regarding pain in children with cancer. Our aim was to formu-
late recommendations for care for children with cancer regarding
assessment and management of pain. In this article, we provide an
overview of our methodology, and briefly present the identified evi-
dence. Subsequent manuscripts will focus on the recommendations,
reporting on (1) pain assessment, (2) management of procedure-
related pain, and (3) management of tumor- and toxicity-related
pain.
2 METHODS
2.1 Multidisciplinary guideline development panel
A full overview of the guideline development panel (GDP) can be found
in Figure 1. The GDPwasmultidisciplinary andmultinational, and con-
sisted of 44 members, recruited through the International Pediatric
Oncology Guidelines in Supportive Care Network (iPOG network)
or solicited by other members.12 All members provided a completed
International Committee of Medical Journal Editors (ICMJE) form for
disclosure of potential conflicts of interest.
The GDP consisted of a core group (CG) and six working groups
(WGs), that focused on assessment and evaluation of pain (WG1),
pharmacological management of tumor-related pain (WG2A), toxicity-
related pain (WG2B), and procedure-related pain (WG2C), and psy-
chological and physical management of tumor- and toxicity-related
pain (WG3A) and procedure-related pain (WG3B).
Great value was placed on incorporating the perspective of the
patient and the family. This was deemed important from a clini-
cal viewpoint but also because we know from previous research
how the involvement of patient representatives positively influ-
enced CPG development.13 Therefore, nine patient representatives
(four cancer survivors and five parents) were solicited through
childhood cancer patient/parent organizations and were involved
in reviewing draft recommendations. Input was used to revise
recommendations. The patient representatives attended a short
training course covering the basics of evidence-based guideline
development.
2.2 Formulation of clinical questions
All WGs formulated clinical questions for topics deemed clinically
relevant. Questions regarding pain assessment were developed in
accordancewith theCOSMIN standards (COnsensus-based Standards
for the selection of health statusMeasurement INstruments), defining
the following: (1) target population, (2) domain, (3) determinant, and
(4) relevant outcomes.14 Questions regarding treatment strategies
were developed according to the PICOS format, defining the following:
(1) patient, (2) intervention, (3) comparison, (4) relevant outcomes,
and (5) study design.
After finalization of the clinical questions, a simple nonweighted
voting procedure using a 10-point scale was carried out to prioritize
these questions for CPG development. For each WG, the clinical
LOEFFEN ET AL. 3 of 12
F
IG
U
R
E
1
O
ve
rv
ie
w
o
ft
h
e
gu
id
el
in
e
d
ev
el
o
p
m
en
t
p
an
el
questions with the highest median score were included (maximum 5
perWG, to keep the workmanageable).
2.3 Rating importance of outcomes
In accordance with the Grading of Recommendations Assessment,
Development and Evaluation (GRADE) methodology, we wanted to
decide on important outcomes before commencing the literature
search, as this would facilitate the discussion for recommendations
later on in the process.15 For all individual clinical questions, WG and
CGmembers voted on the importance of outcomes on a 9-point scale.
Outcomes were categorized according to median score: 1–3: “critical
for decisionmaking,” 4–6: “important, but not critical for decisionmak-
ing,” and 7–9: “low importance for decisionmaking.”15
2.4 Systematic literature search
Together with a medical librarian, we designed two comprehensive
search strategies. The first focused on identifying studies evaluating
measurement properties of pain and distress measurement instru-
ments used in children with cancer (WG1). The second on identifying
randomized controlled trials (RCTs) on interventions to reduce pain in
children with cancer (covering all clinical questions of WG2 andWG3,
as we expected separate clinical question searches would lead to a lot
of overlapping citations and thus double work).
Searcheswere compiled by combining several search filters. If avail-
able, we used search filters of Cochrane Childhood Cancer (CCC).16
We combined four search strategies with the “AND” Boolean operator,
focusing on (1) children, (2) childhood cancer, (3) pain, and (4)measure-
ment properties (WG1) or RCTs (WG2-3). See Supporting Information
Material S1 for complete search strategies.
Several electronic databases were searched, from inception until
March 13, 2018 (initial search March 23, 2017, top-up search March
13, 2018): PubMed/MEDLINE, CINAHL, PsycINFO, HaPI, EMBASE,
AMED, and CENTRAL. We limited results to English language publi-
cations. For identification of additional studies that were not included
in the search, we performed forward and backward citation chasing of
included studies and consulted experts for missing eligible studies.
2.5 Eligibility criteria
Studies had tomeet certain criteria, which differed somewhat per clin-
ical question (see Supporting Information Material S2). Overarching
inclusion criteria were as follows.
Patient criteria. Studies that encompassed children and/or adoles-
cents with cancer, defined as: (1) all participants < 25 years old or a
medianormean≤16years old and (2) at least 75%of participants diag-
nosed with cancer. For the WGs focused on procedure-related pain,
participants had to undergo a relevant minor procedure (e.g., blood
sampling, access to central venous access port), a lumbar puncture pro-
cedure, or a relevant major procedure (e.g., bone marrow aspiration,
bone biopsy).
Intervention /instrument criteria. Studies that investigated a relevant
intervention (pertinent to the clinical question, e.g., gabapentin for
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neuropathic pain, hypnosis for procedural pain) or a relevantmeasure-
ment instrument (e.g., visual analog scale for self-rated pain).
Comparison criteria. Only relevant for intervention studies. Com-
paratorswere active (e.g., placebo, anothermedication) or passive (e.g.,
standard care).
Outcome criteria. Relevant outcomes for measurement properties
studies were defined in accordance with COSMIN (e.g., reliability,
validity).14 For RCTs on interventions, several outcomeswere included
for all clinical questions (e.g., pain intensity, adverseeffects) and several
outcomes differed per clinical question (e.g., ability to eat, duration of
procedure).
Study criteria. Only primary studies with at least 10 participants
were included. In accordance with COSMIN, measurement proper-
ties studies had to state that their aim was to evaluate the clinimet-
ric properties of an existing measurement instrument or to develop
a new measurement instrument.14 For intervention studies, only
RCTs (including crossover RCTs) were included. Studies had to be
published in a peer-reviewed journal, with a full-text available in
English.
2.6 Selection of studies
Aswe anticipated retrieving a large number of citations, we opted for a
three-step fan-out approach (see Figure 2). We began with a selection
based on titles only as this processwas recently found to be potentially
more effective than screening on titles and abstracts.17
Title selection. Two independent reviewers (EL, WT/FC) performed
this selection, which served to exclude studies that were obviously
irrelevant (e.g., older adult population). A conservative approach for
inclusion was used: all citations classified as “include” by at least one
reviewer were included for the next selection round (irrespective
of the other reviewer's classification, no discussion was held). This
approach was applied only during title selection. In all other phases,
discrepancies among two reviewers were discussed in detail and
resolved by consensus (or if necessary by a third reviewer). Review-
ers identified the specific WG(s) which the citation was relevant for,
after which the included citations were fanned out to the relevant
WGs.
To pilot the title selection process, three reviewers (EL, WT, and
RM) appraised the first 250 citations. If absolute agreementwas below
85%, selection criteria were optimized and the pilot was repeated for
the subsequent 250 citations.
Abstract selection. Two independent reviewers (EL, members of
relevant WG) performed the WG-wise selection based on title and
abstract. Reviewers also flagged citations that were relevant for
anotherWG.
Full-text selection. In the final selection round, the same two indepen-
dent reviewers performed theWG-wise selection of full texts in a sim-
ilar manner as the abstract selection.
2.7 Data extraction
For the data extraction, a purpose-built data extraction form includ-
ing manual was developed (see Supporting Information Material S3
and S4); this was pilot tested on three studies by two reviewers (EL
andWT). Subsequently, the formwas completed independently by two
reviewers (same as in full-text selection) for each included study. The
form differed slightly per clinical question, but for all questions cov-
ered: (1) general study information (e.g., title, year); (2) study design
characteristics (e.g., setting, duration); (3) participant characteristics
(e.g., sample size, diagnosis); (4) intervention/instrument characteris-
tics (e.g., intervention, participants per arm); (5) outcome character-
istics (e.g., included outcomes, values); (6) bias assessment (see next
paragraph); and (7) additional information (at the discretion of the
reviewer).
2.8 Quality appraisal
Formeasurementproperties studies, theCOSMINchecklist for assess-
ing methodological quality of such studies was used.14,18 This resulted
in a score per included outcome for each study, that could either be
“excellent,” “good,” “fair,” or “poor.”
For RCTs on interventions, risk of bias of the included studies was
determined according to the criteria used in the Cochrane Risk of Bias
tool, comprising selection bias, performance bias, detection bias, attri-
tion bias, reporting bias, and other bias.19 Per criteria risk of bias was
judged as high, low, or unclear, as per the instructions in the Cochrane
Handbook.19
After this, the quality of evidence for all outcomes was summa-
rized using the GRADE system, where the primary focus is not on
the individual studies, but on the body of evidence, i.e., all included
studies per outcome combined.20 The quality of evidence is classi-
fied as high, moderate, low, or very low. This classification is depen-
dent on the design of the included studies (e.g., RCTs start as
“high”) and various specific factors, i.e., the quality is downgraded for
study limitations, inconsistency, indirectness, imprecision or publica-
tion bias, or upgraded for dose response effect or large magnitude of
effect.21 The GRADE appraisal was performed independently by two
reviewers.
2.9 Data analysis
For intervention studies, the relative intervention effects for each out-
come were calculated, using relative risks including 95% confidence
intervals (CIs) for dichotomous outcomes, and standardized mean dif-
ferences including 95% CIs for continuous outcomes. Meta-analyses
wereperformedwhenmultiple studieswere included that hadanequal
study design and similar patient characteristics. Heterogeneity was
assessed using forest plots and the I2 statistic (cutoff for substan-
tial heterogeneity ≥50%).19 If there was no substantial heterogeneity,
we estimated treatment effects using a fixed-effect model. If substan-
tial heterogeneity was present, we explored possible causes and used
a random-effect model to estimate treatment effects. Meta-analyses
were performed in Review Manager version 5.3 (The Cochrane Col-
laboration, Copenhagen, Denmark). All other statistical analyses were
performed in SPSS version 23.0 (IBM corp., Armonk, NY, USA). For
all statistical tests, a P value of <0.05 was considered statistically
significant.
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F IGURE 2 Flowchart of the study search and selection regarding clinical questions on themanagement of pain in children with cancer
2.10 Synthesis of results
We prepared a narrative synthesis discussing our findings per clinical
question. Tableswith characteristics of included studieswereprepared
and contained information regarding study design, sample, interven-
tion/instrument, where applicable comparison, and outcomes of the
included studies.
For questions regarding measurement properties studies, we pre-
pared a summary of findings tables per construct (e.g., self-reported
pain intensity). To provide a comprehensive overview, we also devel-
oped a quality matrix including information on purpose, number of
studies, age group, and COSMIN quality score.
For questions regarding intervention studies we prepared a sum-
mary of findings table per clinical question, with information for
each included outcome on number of studies, number of participants,
description of intervention, definition of outcome (unit), statistical
method, effect size, and quality of evidence.
2.11 Project groupmeeting in Amsterdam
All project members were invited to a two-day in-person consensus
conference in Amsterdam (NL) in February 2018. Of 44 members, 36
attended (82%). The majority of the meeting proceedings consisted
of discussing included studies, evidence summaries and formulating
recommendations in small WGs setting. In addition, total group meet-
ings were held to discuss the draft recommendations and to devise the
way forward. Decisions were made through group discussion and con-
sensus. In all steps, except the formulation of final recommendations,
a voting procedure was performed (majority voting system) in case
of absence of unanimity. Final recommendations had to be supported
unanimously by allWGmembers.
2.12 Formulation of recommendations;
evidence-to-decision table
For each clinical question, theWGs completed an evidence-to-decision
(EtD) framework. Recently, GRADE published the EtD-framework,
which is a systematic and transparent approach to formulating health-
care recommendations.22 This framework consists of 11 questions in
six domains and facilitates taking both the evidence and the repre-
sented expert knowledge into account. After an EtD framework was
completed, we formulated an overall conclusion in which the bene-
fits and harms are weighed. On the basis of these conclusions, recom-
mendations for clinical care were formulated. These EtD frameworks
and accompanying recommendationswere also discussed in a separate
meeting with the patient representatives, to explore their values and
preferences and so validate and/or expand decision-making. If the lat-
ter led to alterations in the recommendations, these were discussed
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again in the relevant WG. Final recommendations had also to be sup-
ported unanimously by the patient representatives panel.
2.13 Additional evidence searches
For someof the includedclinical questionsonpainmanagement, the lit-
erature reviewyieldedvery fewornoeligible studies, leading to insuffi-
cient evidence upon which to base a recommendation. For these ques-
tions, theCGproposed a flowchartwith steps to follow that the project
group subsequently agreedwith (see Figure 2).
For clinical questions regarding assessment of painwith insufficient
evidence, we searched for systematic reviews (SRs), meta-analyses
(MAs), and CPGs concerning pain measurement instruments in all
child populations (indirect evidence). For all treatment questions
with insufficient evidence we searched for lower quality evidence
(i.e., nonrandomized comparison trials) in children with cancer, and
for most questions we also searched for SRs, MAs, and CPGs in
other child populations (e.g., for distraction techniques during proce-
dures). For questions with a pathophysiology specific to cancer (e.g.,
chemotherapy-induced mucositis), we did not search for literature
from other child populations, but only for adult oncology CPGs.
The systematic searches for these questions were more focused
than the initial searches (see Supporting Information Material S1).
For the non-RCTs, we included all primary studies with a comparison
design (parallel, crossover, pre-post), aminimumof10participants, and
published since 2000. For the SRs, MAs, and CPGs, we included only
studies that compliedwithminimal quality criteria, andwere published
since 2013 (see Figure 2).
After the selection of studies and extraction of data, the retrieved
information was added to the relevant evidence summary, which was
subsequently used to complete the updated EtD framework. Formula-
tionof recommendations then commenced in a similarmanner as in the
previous phase.
2.14 Funding source
The project “Towards evidence-based guidelines for supportive care
in childhood oncology” is supported by the Alpe d'HuZes founda-
tion/Dutch Cancer Society (RUG 2013-6345). The funding source had
no role in the study design, in the collection, analysis, and interpreta-
tion of the data, in the preparation of themanuscript, or in the decision
to submit themanuscript for publication.
3 RESULTS
3.1 Clinical questions
The WGs formulated 89 clinical questions (see Supporting Informa-
tion Material S2). After the voting rounds, 22 clinical questions were
included (Table 1). Prioritized outcomes differed per clinical question;
however, for the questions on pain management strategies, self-rated
pain intensitywas consistently prioritized as themost critical outcome.
3.2 Systematic review
See Figure 3 for a PRISMA flowdiagramof the selection process.23 See
Supporting Information Material S5 for a list of excluded studies that
were read in full text. In the title selection process pilot, agreementwas
excellent (231 of 250 citations [92.4%] had identical scores by all three
reviewers).
The literature search for clinical questions regarding assessment of
pain yielded 2,857 citations. Of these, 79 articles were read in full text,
of which 13 studies were included: two on self-rating of pain intensity
using numbers, six on behavioral distress assessment, two on neuro-
pathic pain, and three onmultidimensional instruments.24–36 Unfortu-
nately for self-rating of pain intensity using numerical rating scales and
for “simple” proxy ratings, no studies were eligible for inclusion.
For clinical questions on painmanagement strategies, the literature
search yielded 11 159 citations, of which 194 articles were read in
full text and eventually 55 RCTs were included. Regarding pharmaco-
logical management of tumor-related pain, no RCTs were eligible for
inclusion. With regard to pharmacological management of treatment-
related pain, seven RCTs were included: five on mucositis, one on neu-
ropathic pain, and one on phantom limb pain.37–42 Only one RCT was
included regarding psychological and physical management of tumor-
and treatment-related pain, concerning physical therapy.43 Regarding
pain during procedures, therewere 33RCTs included on pharmacolog-
ical management: seven on minor procedures, eight on lumbar punc-
tures, and 13 onmajor procedures.44-76 For psychological and physical
management of pain during procedures, 15 RCTs were included: six on
hypnosis, five on active distraction, two on passive distraction, and two
on combining treatment modalities.69,71,77–89
4 DISCUSSION
The primary focus in children with cancer has initially, understand-
ably, been on improving survival, supportive care has long been a
relatively unexplored niche. However, with current survival rates and
the high burden of cancer and its treatment on patients and their
families, improving supportive care is increasingly acknowledged as
an area that deserves attention.90,91 To improve care, we initiated a
project to develop childhood cancer supportive care CPGs, of which
the development of a CPG regarding pain in children with cancer
is one of the initial foci.11 We executed this project in a very rigor-
ous manner and described our methods in this article to promote
transparency and to inspire and educate others on the verge of
initiating a supportive care CPG project. Currently, we are developing
recommendations, which will be published in a three-part series: (1)
assessment of pain, (2) pharmacological, psychological, and physical
management of tumor- and treatment-related pain, and (3) pharmaco-
logical, psychological, and physical management of procedure-related
pain.
One of the strengths of this project is also an important challenge.
Because we aspired to develop as comprehensive a CPG as possi-
ble, we included many clinical questions. When all these questions
are answered, the emerging clinical and/or research recommendations
will help healthcare professionals greatly in their daily work. However,
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TABLE 1 Included clinical questions
Patient Instrument Critical outcomes (as prioritized)
Childrenwith cancer Pain intensity: self-rating
(numbers, pictures)
Reliability, validity, clinical utility,
responsiveness, interpretability
Childrenwith cancer “Simple” rating by proxy Reliability, validity, clinical utility,
interpretability
Childrenwith cancer Behavioral distress
assessment
instruments
Reliability, validity, clinical utility,
responsiveness, interpretability
Childrenwith cancer Neuropathic pain Reliability, validity, clinical utility,
interpretability
Childrenwith cancer Multidimensional
instruments
Reliability, validity, clinical utility,
interpretability
Patient Intervention Control Critical outcomes (as prioritized)
2A Childrenwith cancer Pharmacological
therapies tomanage
nociceptive pain
Any Pain intensity (self-rated), distress (self-rated),
quality of life (self-reported), adverse effects,
distress (“simple” proxy rating), behavioral
distress, changes in physical functioning,
changes in general functioning
2A Childrenwith cancer Pharmacological
therapies tomanage
bone pain
Any Pain intensity (self-rated), distress (self-rated),
quality of life (self-reported), adverse effects,
distress (“simple” proxy rating), behavioral
distress, changes in physical functioning,
changes in general functioning
2A Childrenwith cancer Pharmacological
therapies tomanage
tumor-related
neuropathic pain
Any Pain intensity (self-rated), distress (self-rated),
quality of life (self-reported), adverse effects,
distress (“simple” proxy rating), behavioral
distress, changes in physical functioning,
changes in general functioning, sleep
2A Childrenwith cancer Opioid-sparing Any Pain intensity (self-rated), distress (self-rated),
quality of life (self-reported), adverse effects,
changes in physical functioning, changes in
general functioning
2A Childrenwith cancer Role of invasive
procedures
Any NA
2B Childrenwith cancer Pharmacological
therapies tomanage
chemotherapy-induced
neuropathic pain
Any Pain intensity (self-rated), distress (self-rated),
quality of life (self-reported), adverse effects,
distress (“simple” proxy rating), behavioral
distress, changes in physical functioning,
changes in general functioning, quality of life
(reported by proxy), global judgement of
satisfaction with treatment
2B Childrenwith cancer Pharmacological
therapies tomanage
pain frommucositis
Any Pain intensity (self-rated), distress (self-rated),
quality of life (self-reported), adverse effects,
distress (“simple” proxy rating), behavioral
distress„ quality of life (reported by proxy),
duration of therapeutic effect, global
judgement of satisfaction with treatment,
oral intake, ability to eat
2B Childrenwith cancer Pharmacological
therapies tomanage
pain from constipation
due to opioids
Any Pain intensity (self-rated), adverse effects,
distress (self-rated), distress (“simple” proxy
rating), change in dose of opioids
2B Childrenwith cancer Pharmacological
therapies tomanage
phantom limb pain
Any Pain intensity (self-rated), distress (self-rated),
quality of life (self-reported), adverse effects,
distress (“simple” proxy rating), behavioral
distress, changes in physical functioning,
changes in general functioning, quality of life
(reported by proxy), duration of therapeutic
effects, global judgement of satisfaction with
treatment, need for “classic” (nociceptive)
pain interventions
2B Childrenwith cancer Pharmacological
therapies tomanage
anti-gd2 antibody
infusion-related pain
Any Pain intensity (self-rated), distress (self-rated),
adverse effects, distress (“simple” proxy
rating), behavioral distress, quality of life
(self-reported), changes in physical
functioning, sleep
(Continues)
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TABLE 1 (Continued)
Patient Instrument Critical outcomes (as prioritized)
2C Childrenwith cancer
undergoing aminor
procedure
Pharmacological
therapies to reduce
procedure-related pain
and distress
Any Pain intensity (self-rated), distress (self-rated),
behavioral distress, adverse effects
2C Childrenwith cancer
undergoing a lumbar
puncture
Pharmacological
therapies to reduce
procedure-related pain
and distress
Any Pain intensity (self-rated), distress (self-rated),
adverse effects, distress (“simple” proxy
rating), behavioral distress, procedure
success
2C Childrenwith cancer
undergoing amajor
procedure
Pharmacological
therapies to reduce
procedure-related pain
and distress
Any Pain intensity (self-rated), distress (self-rated),
adverse effects, distress (“simple” proxy
rating), behavioral distress
3A Childrenwith cancer Physical therapy Any Pain intensity (self-rated), distress (self-rated),
quality of life (self-reported), changes in
general functioning, changes in physical
functioning, adverse effects
3A Childrenwith cancer Active distraction Any Pain intensity (self-rated), quality of life
(self-reported), distress (self-rated), changes
in general functioning, global judgement of
satisfaction with treatment, adverse effects
3A Childrenwith cancer Passive distraction Any Pain intensity (self-rated), quality of life
(self-reported), distress (self-rated), changes
in general functioning, global judgement of
satisfaction with treatment, adverse effects
3A Childrenwith cancer Meditation/mindfulness Any Pain intensity (self-rated), distress (self-rated),
quality of life (self-reported), global
judgement of satisfaction with treatment,
adverse effects
3A Childrenwith cancer Guided imagery Any Pain intensity (self-rated), quality of life
(self-reported), distress (self-rated), changes
in general functioning, global judgement of
satisfaction with treatment, adverse effects
3B Childrenwith cancer
undergoing a painful
procedure
Active distraction Any Pain intensity (self-rated), distress (self-rated),
distress (“simple” proxy rating), behavioral
distress, fear for futuremedical procedures,
adverse effects
3B Childrenwith cancer
undergoing a painful
procedure
Combination of
modalities
Any Pain intensity (self-rated), distress (self-rated),
distress (“simple” proxy rating), behavioral
distress, global judgement of satisfactionwith
treatment, fear for futuremedical
procedures, adverse effects
3B Childrenwith cancer
undergoing a painful
procedure
Hypnosis Any Pain intensity (self-rated), distress (self-rated),
distress (“simple” proxy rating), behavioral
distress, fear for futuremedical procedures,
adverse effects
3B Childrenwith cancer
undergoing a painful
procedure
Passive distraction Any Pain intensity (self-rated), distress (self-rated),
distress (“simple” proxy rating), behavioral
distress, fear for futuremedical procedures,
adverse effects
3B Childrenwith cancer
undergoing a painful
procedure
Parent coaching Any Pain intensity (self-rated), distress (self-rated),
distress (“simple” proxy rating), behavioral
distress, fear for futuremedical procedures,
adverse effects
the obvious drawback of including multiple clinical questions is that it
might lead to almost unmanageable amounts of work. We have, how-
ever, made efforts to reduce this without compromising quality, i.e., by
combining search strategies.
The biggest challenge in the development of this CPGwas handling
situations in which there was either very little or very low quality evi-
dence. As previously mentioned, research in supportive care in child-
hood cancer is a relatively new area of investigation, thus the evidence
base is small. Nevertheless, we were still disappointed by the scarcity
of high-quality studies conducted in this important field of cancer care.
This left us with several suboptimal options: omitting the clinical ques-
tion, basing a recommendationuponexpert consensus, or searching for
lower quality and/ormore indirect evidence. In a recent paper from the
GRADE guidelines series, the GRADE working group acknowledged
that clinicians canbe frustratedwhena guideline does not actually pro-
vide guidance.92 Guideline panels are therefore encouraged to make
LOEFFEN ET AL. 9 of 12
F IGURE 3 A, Flowchart of the citation screening and selection, working group 1. B, Flowchart of the citation screening and selection, working
groups 2A, 2B, 2C, 3A, 3B
an effort to provide recommendations, even when evidence is scarce
or of lowquality.Our guideline panel fully endorsed this aim; neverthe-
less, the panel also did not want to base a recommendation solely on
expert opinion. Therefore, we devised a method to identify additional
evidence (be it either of lower quality or more indirect) upon which to
base our recommendations.
In addition, we encouraged patient representatives to share their
values and preferences as so to contribute to formulating the recom-
mendations. Working together closely with patient representatives,
and providing them with training in evidence-based guideline devel-
opment, will facilitate a CPG in which the patient perspective is inter-
weaved.
The lack of identified high-quality studies also emphasizes the
importance of undertaking studies focusing on effective painmeasure-
ment and management, as pain has been acknowledged repeatedly as
one of the most important adverse effects of childhood cancer and its
therapy.1 Large randomized studies are needed, and as patient num-
bers are relatively small we encourage these to be multicentered and
international in scope. In our upcoming CPGs, detailed research rec-
ommendations will be includedwhich can serve to inform the research
agenda for the coming decade.
In conclusion, with the improving cure rates of childhood can-
cer, it is of the utmost importance to develop high-quality evidence-
based guidelines for supportive care, to reduce variabilities in care
and improve patient outcomes. In this project, we took the first steps
toward a comprehensive CPG regarding assessment and pharmaco-
logical, psychological, and physical management of tumor-, treatment-,
and procedure-related pain in children with cancer.
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